Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis

PHASE3CompletedINTERVENTIONAL

Enrollment

204

Participants

Timeline

Start Date

January 15, 2016

Primary Completion Date

November 28, 2018

Study Completion Date

December 11, 2020

Conditions

Eosinophilic Esophagitis

Interventions

DRUG

Budesonide 0.5mg orodispersible tablet twice daily

DRUG

Budesonide 1mg orodispersible tablet twice daily

DRUG

Placebo orodispersible tablet twice daily

Trial Locations (1)

Center for Digestive Diseases Eppendorf, Hamburg